Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
LOXO Oncology, Inc
Scientific Title
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors